Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ironwood Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Ironwood Pharmaceuticals, Inc.’s stock price such as:

• Ironwood Pharmaceuticals, Inc.’s current stock price and volume
• Why Ironwood Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for IRWD from analysts
• IRWD’s stock price momentum as measured by its relative strength

About Ironwood Pharmaceuticals, Inc. (IRWD)

Before we jump into Ironwood Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Want to learn more about Ironwood Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of May 21, 2026, 1:01 PM, CST, Ironwood Pharmaceuticals, Inc.’s stock price was $3.760.

Ironwood Pharmaceuticals, Inc. is down 4.08% from its previous closing price of $3.920.

During the last market session, Ironwood Pharmaceuticals, Inc.’s stock traded between $3.705 and $3.850. Currently, there are approximately 163.45 million shares outstanding for Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 6.4, which is low compared to the Biotechnology industry median of 18.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Ironwood Pharmaceuticals, Inc. Stock Price History

Ironwood Pharmaceuticals, Inc.’s (IRWD) price is currently down 8.85% so far this month.

During the month of May, Ironwood Pharmaceuticals, Inc.’s stock price has reached a high of $4.880 and a low of $3.420.

Over the last year, Ironwood Pharmaceuticals, Inc. has hit prices as high as $5.780 and as low as $0.550. Year to date, Ironwood Pharmaceuticals, Inc.’s stock is up 11.57%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ironwood Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there were 0 analysts who downgraded Ironwood Pharmaceuticals, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Ironwood Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ironwood Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ironwood Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ironwood Pharmaceuticals, Inc. (IRWD) by visiting AAII Stock Evaluator.

Relative Price Strength of Ironwood Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, Ironwood Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 47.19%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Ironwood Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ironwood Pharmaceuticals, Inc. Stock Price: Bottom Line

As of May 21, 2026, Ironwood Pharmaceuticals, Inc.’s stock price is $3.760, which is down 4.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ironwood Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.